International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 1993
Treatment of polycystic ovarian disease during adolescence with ethinylestradiol/cyproterone acetate versus a D-Tr-6-LHRH analog.
Клиническое исследованиеСравнительное исследованиеСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Creatsas G, Hassan E, Deligeoroglou E, Tolis G, Aravantinos D
Аннотация
OBJECTIVE: This study was undertaken to compare the clinical and endocrinological results of two kinds of treatment on adolescents with polycystic ovarian disease (PCOD).
METHOD: Forty-five adolescents with PCOD were randomly allocated into two groups, treated either with ethinylestradiol (EE)/cyproterone acetate (group A) or the GnRH analog D-Tr-6-LHRH (group B).
RESULT: No significant changes were detected on the body mass index and waist-hip circumference. A significant improvement of hirsutism was noticed in both groups of patients. A normal menstrual period was recorded in group A adolescents while all group B patients became amenorrheic. A favorable decrease of ovarian volume was detected in both groups. LH/FSH ratio and delta 4-androstenedione serum levels were found significantly reduced in both groups in comparison to pre-treatment levels. The comparison between the two groups, after 6 months, showed significantly lower values of LH/FSH ratio in group B cases.
CONCLUSION: Both forms of treatment are safe and effective to a various degree for the management of PCOD adolescents.
METHOD: Forty-five adolescents with PCOD were randomly allocated into two groups, treated either with ethinylestradiol (EE)/cyproterone acetate (group A) or the GnRH analog D-Tr-6-LHRH (group B).
RESULT: No significant changes were detected on the body mass index and waist-hip circumference. A significant improvement of hirsutism was noticed in both groups of patients. A normal menstrual period was recorded in group A adolescents while all group B patients became amenorrheic. A favorable decrease of ovarian volume was detected in both groups. LH/FSH ratio and delta 4-androstenedione serum levels were found significantly reduced in both groups in comparison to pre-treatment levels. The comparison between the two groups, after 6 months, showed significantly lower values of LH/FSH ratio in group B cases.
CONCLUSION: Both forms of treatment are safe and effective to a various degree for the management of PCOD adolescents.
Предметные рубрики MeSH
AdolescentAndrostenedioneCyproterone AcetateDehydroepiandrosteroneDehydroepiandrosterone SulfateDelayed-Action PreparationsDinoprostoneDrug Therapy, CombinationEthinyl EstradiolFemaleFollicle Stimulating HormoneHumansLuteinizing HormonePolycystic Ovary SyndromeProlactinProspective StudiesSex Hormone-Binding GlobulinTestosteroneTriptorelin Pamoate